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Summary 
Plasmodium falciparum malaria merozoites invade  human erythrocytes bearing sialic acid in a 
multistage process involving the sialic acid-dependent binding of a malaria molecule, the 175-kD 
erythrocyte binding antigen (EBA-175). We show here that after the initial interaction of EBA- 
175 with its sialic add-containing erythrocyte determinant, endogenous  proteases can cleave  EBA-175 
to 65-kD fragment(s), whose binding to erythrocytes is sialic acid independent. A 65-kD fragment 
was immunoprecipitated by antibodies against peptides between residues 354 and 1061 but not 
beyond residue 1062. Binding experiments utilizing combinations of native protein, expression- 
PCR-synthesized EBA-175 polypeptides, peptide synthesis,  and antibodies, demonstrated that 
sialic acid-independent binding could be further mapped to a  small  (about 40-amino acid) 
homologous part of the dimorphic allelic region of EBA-175, residues 898-938 (Camp strain 
numbering). These data support a two-step binding hypothesis and are discussed in relation to 
the formation of a junction between the merozoite and the erythrocyte, and the finding that 
after the interaction of some viruses with specific cellular receptors, they undergo conformational 
changes or cleavage permitting membrane fusion with the host cell. 
C 
urrent Plasmodium falciparum vaccine strategies include 
the development of a multistage subunit vaccine con- 
sisting of antigens from different stages of the parasite life 
cycle (1, 2). As the primary pathophysiologic events of fal- 
ciparum malaria occur during the erythrocytic or blood stages, 
merozoite antigens would represent important components 
of such a vaccine. Among the best candidates for inclusion 
into a blood stage vaccine are merozoite receptors for eryth- 
rocyte ligands through which host immune responses might 
block erythrocyte binding and invasion. Camus and Hadley 
(3)  described a  175-kD  P. fakiparum  antigen (erythrocyte 
binding antigen [EBA-1751]) that appears to be involved in 
the attachment of the merozoite to the erythrocyte. EBA- 
175 binds to a sialic acid containing glycophorin-associated 
ligand on R.BCs in a manner that correlates with invasion. 
The gene encoding EBA-175 has been cloned and sequenced 
from two strains of P.fakiparum (Camp and FCK3) that show 
restriction fragment length polymorphism (4, 5). The EBA- 
1 Abbreviations used in this paper: EBA-175, erythrocyte binding antigen 
175; EBP, erythrocyte binding protein; E-PCR, expression-PCR; HA, 
hemagglutinin;  huE, human erythrocyte; rhE,  Rhesus erythrocyte. 
175 gene is largely conserved in these strains except for a 423-bp 
region found only in FCR3 (F seg) and a 345-bp segment 
found only in Camp C (C seg). These allelic regions are con- 
served in all cultured and wild isolates examined to date (5, 
6). Polyclonal antibodies generated to a conserved region of 
EBA-175 immediately downstream from these aUelic regions 
have been shown to inhibit invasion of RBCs by homolo- 
gous merozoites in vitro (4, 7). However, the molecular basis 
of the interaction of EBA-175 with uninfected RBCs is un- 
known. Understanding the molecular interactions of P. Jal- 
ciparurn erythrocyte binding proteins with URBCs may help 
define the sequence of events resulting in merozoite invasion 
and may identify functional domains of parasite proteins that 
would be important to evaluate for inclusion in a subunit 
vaccine. The available techniques to map functional domains 
of large molecular weight proteins are dependent on cloning, 
sequencing, and protein purification. These approaches suffer 
from inflexibility and require an extensive allocation of time 
and resources. We recently developed a rapid noncloning in 
vitro  gene  expression  system,  expression-PCK (E-PCR), 
ideally suited for structure-function analysis of proteins (8). 
In this study we examine the molecular basis of erythrocyte 
binding by EBA-175 utilizing E-PCR in combination with 
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to RBCs in vitro, native EBA-175 is cleaved to a 65-kD frag- 
ment that remains bound to the erythrocyte. The binding 
of this 65-kD fragment appears to involve a RBC determinant 
distinct  from that  of full-length  EBA-175.  These observa- 
tions may further elucidate the sequence of molecular inter- 
actions  required  for  erythrocyte invasion  by P. fakiparum 
merozoites. 
Materials and Methods 
Parasites and  Labeled  Culture Supernatants.  Cloned  Camp 
(Malaysia) and FCR3 (Africa) strains of P.fakiparum were cultured 
and synchronized as previously described (9).  Schizont-infected 
erythrocytes were Percoll enriched (10) and metabolically labeled 
at  1.5  x  107/ml with 50/~Ci/mL  [3H]isoleucine  in isoleucine- 
deficient RPMI-1640 culture medium containing 10% human serum 
(3, 11). The parasites were cultured for 16 h at 37~  to allow matu- 
ration of the schizonts and release of merozoites. The supernatants 
were collected by centrifugation at 300 g-min mm- 1 (9) and stored 
at  -80~ 
Erythrocytes  andEnzyme Pretreatments.  Human (huE) and Rhesus 
erythrocytes (thE) were collected in acid citrate dextrose solution 
and stored at 4~  Washed erythrocytes were treated with 50 U/ml 
Vibrio cholerae neuraminidase (Gibco BRL, Kockville, MD),  1.0 
mg/ml Trypsin (Sigma Chemical Co., St. Louis, MO), or 0.2 mg/ml 
chymotrypsin (Sigma) as previously described (3, 12). The treated 
erythrocytes were extensively washed before being used in binding 
studies. 
Binding and Elution  from Erythrocytes.  Affinity-purified EBA-175 
was prepared using a modification of the method of Haynes et al. 
(13). Briefly, washed erythrocytes (100 #1) and culture supernatant 
(200 #1) were mixed for 30 min at room temperature. The suspen- 
sion was layered over silicon oil (GE versilube FS0) and centrifuged 
for 30 s at 13,000 g. EBA-175 was eluted from the erythrocyte pellet 
with high salt buffer (KPMI-1640 media supplemented with 1 M 
NaC1 with or without 2 mM PMSF [Sigma]) for 10 rain at room 
temperature. After repelleting the erythrocytes, the eluate was re- 
moved and prepared for rebinding studies or for analysis by SDS- 
PAGE.  E-PCK in vitro synthesized EBA-175 polypeptides were 
bound and eluted in the same way as native EBA-175. 
Rebinding and Sequential Elution.  Erythrocyte binding proteins 
(EBP) were bound to the or huE (in the presence  or absence of 
2 mM PMSF) and spun through oil as above. The RBC pellet was 
then resuspended in 100 #1 of serum-free media, incubated at 37~ 
for 60 min, spun through oil, and eluted with 1 M NaC1 as above. 
Eluates were diluted to 100 #1 with complete media (RPMI-1640 
media plus 10% human serum) and dialyzed for 60 min against 
complete media. This dialyzed fraction was then rebound to un- 
treated and enzyme-treated rhE or huE (in the presence of PMSF) 
as described above. Rebound EBPs were then either eluted with 
salt or sequentially eluted, first with 50 mM 2,3-sialyllactose (Sigma) 
then with  1 M  NaC1. 
These eluted fractions were heated with an equal volume of 2 x 
SDS  sample  buffer,  separated  by SDS-PAGE  and  processed  for 
fluorography (14). 
Immunoprecipitation.  Immunoprecipitation of radiolabeled cul- 
ture supernatants was performed with polyclonal monospecific an- 
tisera raised in mice and rabbits against  the following peptides of 
the Camp strain of EBA-175 (4): peptide N1 (residues 354--377); 
peptide P2 (residues 939-969); peptide P5 (residues 970-1014); pep- 
tide P6 (residues 1015-1061); and peptide P4 (residues 1062-1103). 
Immunoprecipitations were performed as previously described (15) 
and precipitated antigens were detected by fluorography. 
In Vitro Synthesis of  EBA-175 using E-PCR.  The gene encoding 
EBA-175 was derived from genomic DNA of the Camp and FCR3 
strains of  P.faki~rum. Overlapping polypeptides of EBA-175 were 
synthesized using E-PCR as previously described (8). Gene frag- 
ments of EBA-175 (see Fig. 3) were amplified from genomic DNA 
in an automated thermocycler (Perkin-Elmer Cetus Corp., Nor- 
walk,  CT).  100  ng  of genomic DNA  was  added  to  a  100-#1 
amplification  mixture containing 50 pmol each of an appropriate 
5' and 3' primer (see Table 1) derived from the published sequences 
of EBA-175 from Camp and FCR3 strains  of P. fakiparum  (4,  5) 
and either 2.5 U  of Taq (Perkin-Elmer Cetus Corp.) or 5 U  of 
Vent polymerase (New England Biolabs Inc., Beverly, MA). The 
reaction mixture was initially denatured at 95~  for 5 min fol- 
lowed by 25 cycles of amplification (94~  for 30 s, 50-55~  for 
30 s, and 72~  for 2-6 min) followed by an extension of 72~ 
for 7 min. PCR products were separated on a 2% low melt agarose 
gel, and the DNA bands were excised and stored at 4~ 
E-PCR was performed by mixing equal molar concentrations 
of the universal  promoter (UP) and the desired  amplified P. Jal- 
ci~rum gene fragment (after melting at 60~  together with 1.3 U 
of Taq polymerase or 2.5 U of Vent polymerase (without primers) 
for 15 cycles, (each consisting of 30 s at 94~  30 s at 25~  and 
2-6 rain at 72~  Samples were then amplified for an additional 
25 cycles (30 s at 94~  30 s at 55~  and 2 min at 72~  after 
adding 50 pmol of  both primer H3T7 and the 3' gene-specific primer 
(Table 1) and 1.3 U ofTaq polymerase or 2.5 U of Vent polymerase. 
E-PCR products were extracted once with chloroform, precipi- 
tated with ethanol, and resuspended in 10 #1 of RNase-free water. 
In Vitro Transcription.  DNA templates produced by E-PCR were 
added to a 50-/~1 transcription reaction containing 40 mM Tris- 
HCL, pH 8.0, 8 mM MgC12, 2 mM spermidine,  10 mM NaC1, 
10 mM dithiothreitol (DTT), 40 U of RNasin (Promega, Madison, 
WI), 500/~M each of rATP, rCTP, rGTP, and rUTP, and 25 U 
of T7 RNA polymerase (Promega). The reaction was incubated 
at 37~  for 60 min. The DNA template was digested with 1 U 
of RQ1 DNase (Promega) at 37~  for 10 min followed by phenol 
extraction, ethanol precipitation, and resuspension in 10/xl RNase- 
free water. 
In Vitro Translation.  EBA-175  mRNA produced in the T7 tran- 
scription reaction was translated in a wheat germ or rabbit reticulo- 
cyte cell-free system in the presence of [3H]leucine or [3SS]methi- 
onine, according to the manufacturers' specifications  (Promega). 
The efficiency of protein synthesis  was determined by analyzing 
2-/~1 samples of the reaction for TCA-precipitable radioactivity, as 
measured by liquid scintillation counting. The 3H- or 3sS-labeled 
proteins produced by cell-free translation were analyzed by SDS- 
PAGE and fluorography. Functional activity of synthesized pro- 
teins was assessed by immunoprecipitation and erythrocyte binding 
studies as described above. Equivalent TCA-precipitable counts of 
synthesized proteins were used in all binding and immunoprecipi- 
tation studies. 
Immunization with E-PCR Synthesized Protein.  In vitro transla- 
tion was performed as described above but without the addition 
of isotope and with equal molar concentrations of amino acids. 
BALB/c mice were immunized directly with cold E-PCR synthe- 
sized proteins. 100/~1 (1(X)-200  ng) of synthesized protein in a trans- 
lation mixture was injected subcutaneously in CFA.  Mice were 
boosted twice at 2-wk intervals with 100/~1 of protein in IFA. Con- 
trol mice were similarly immunized by using translation mixture 
to which no EBA mRNA had been added. 
Production of Antisera to Peptides.  Synthetic peptides with an 
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or lysine (peptide CP-1) residue were generated on a protein syn- 
thesizer (model 430A; Applied Biosystems, Inc., Foster City, CA). 
Analytical HPLC and quantitative amino acid analysis confirmed 
the identity and purity of the products. Peptides were conjugated 
to KLH with glutaraldehyde (16). Conjugated proteins were dia- 
lyzed with two changes of 4 liters of PBS for 48 h (4~  Rabbits 
(peptides P4 and CP-1) and mice (peptides P2, P5, P6, and N1) 
were immunized with conjugated proteins: primary immunizations 
were emulsified  in CFA and boosting immunizations were emulsified 
in IFA. 
Binding Inhibition Assays.  EBA-175 and the 65-kD fragment, 
generated by binding to huE, were salt eluted, dialyzed, and re- 
bound to untreated hue as described above, but rebinding was per- 
formed in the presence of increasing concentrations of  peptide CP-1 
(1, 10, and 100 mM peptide CP-1) or anti-CP-1 sera in complete 
media. Rebinding of EBAo175 and the 65-kD fragment was also 
examined in the presence of a 100-mM concentration of control 
peptide 4. Rebound samples were then salt eluted and analyzed 
by SDS-PAGE and fluorography. 
Results 
Erythrocyte  Binding  by EBA-175  and  its  65-kD  Processed 
Product.  Erythrocyte binding by EBA-175 was studied using 
an in vitro RBC-binding assay. In these assays, metabolically 
labeled EBP are identified by affinity purification on erythro- 
cytes (12). Under these conditions, native EBA-175 binds to 
a sialic acid-dependent ligand and is cleaved to a 65-kD frag- 
ment recognized by monospecific antisera to EBA-175 (Figs. 
1, A  and B, and 2). Cleavage is inhibited in the presence of 
protease inhibitors and enhanced cleavage is observed when 
EBA-175 is experimentally bound to rhE. To characterize the 
binding of EBA-175  and its processed products to erythro- 
cytes, rebinding and sequential dution studies were performed 
with both rhE and huE. In these experiments, EBPs were 
affinity purified on thE or huE, eluted with salt, dialyzed, 
and then rebound to the or huE. Rebinding was performed 
in the presence of PMSF to prevent additional cleavage of 
full-length EBA-175.  With this approach, it was possible to 
assess the binding characteristics of the isolated 65-kD frag- 
ment independent from the binding requirements of the full- 
length EBA-175  molecule. When EBPs were rebound and 
eluted with salt from rhE, both full-length EBA-175  and a 
doublet of',~65 kD were recovered (Fig. 1 A, lane I). When 
rebound to the and sequentially eluted, first with 2-3 sialyl- 
lactose (Fig.  I  A, lane 2) followed by 1 M  NaC1 (lane 3), 
EBA-175 and the 65-kD fragment were differentially recov- 
ered. Full-length EBA-175 was eluted almost completely with 
sialyllactose,  however, the 65-kD doublet was recovered pri- 
marily with 1 M  NaC1.  No detectable EBA-175  or 65 kD 
remained on these erythrocytes after sequential elution, as 
determined by SDS-PAGE of the RBC pellet (data not shown). 
To enhance the production of the 65-kD fragment, EBPs 
initially generated in the absence of protease inhibitors were 
also used for rebinding experiments (Fig.  1 A, lane 5). Se- 
quential elution studies performed using EBPs prepared in 
this fashion, also showed differential elution of EBA-175 and 
the 65-kD fragment (Fig.  1 A, lanes 7 and 8). To ensure that 
sufficient quantities  of both full-length EBA-175  and the 
65-kD fragments were present for the subsequent studies, 
equal volumes of eluted EBPs, initially prepared in the pres- 
ence of protease inhibitors  (as in Fig.  1 A, lane I) and in 
the absence of protease inhibitors (as in Fig.  1 A, lane 5), 
Table  1.  Oligonucleotides  (5' to 3') 
Oligo  Position  Sequence 
1  1-21" 
2  63-84 
3  1092-1110 
4  1623-1647 
5  2277-2298 
6  2607-2625 
7  2928-2946 
8  2952-2973 
9  3458-3476 
10  4333-4306 
F1  2332-235311 
F2  2727-2748U 
H3T7 
ATGGCACTGATGAAATGTAATATTAGTATA* 
ATGGCACTGGCTAGGAATGAATATGATATA~ 
ATGGCACTGATGAAATATAGAGATTGG* 
ATCAGCGAAAGTTTTATTTATGATS 
ATGGCACTGACTTCGCAAGAAGCAGTTCCT* 
ATGGCACTGAAGGAATTAGAAGATCAA~ 
TAAACTATTTCCTCCTTCS 
ATGGCACTGCATGAAGAGGTGAAAGAACAT* 
CGTTTTGTACATGTGTGGS 
CTGCTCCTGCATAATATGGCATACCTAS 
ATGGCACTGCGTACGGATGAACGAAAAAAT~ 
CTCTGTATCAGAACTTCCACTs 
CCAAGCTTCTAATACGACTCACTATAGGG 
* Position in Camp strain of P. fakiparum. 
t Sequence  includes splice region for E-PCtL. 
S Antisense oligonucleotide. 
H  Position in FCR3 strain of P. fakiparum. 
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EBPs, bound  and ehted from huE,  immunoprecipitated with various 
monospedfic antibodies, and analyzed by 10%  SDS-PAGE and fluorog- 
raphy.  (Lane I) Control EBA-175 and its 65-kD fragment, eluted with 
salt from huE. (Lane 2) salt ehate immunopreeipitated  with antisera gener- 
ated to peptide N1 (residues 354 to 377 in EBA-175). (Lane 3) Salt eluate 
immunoprecipitated with antisera generated to peptide P2 (residues 939 
to 969 in EBA-175). (Lane 4) Salt duate immunopredpitated with antisera 
generated to peptide P5 (residues 970 to 1014 in EBA-175). (Lane 5) Salt 
eluate immunoprecipitated with antisera generated to peptide P6 (residues 
1015 to 1061 in EBA-175). (Lane 6) Salt eluate immunoprecipitated with 
antisera generated to peptide P4 (residues 1062 to 1103 in EBA-175). (Lane 
7) Camp EBA-175 salt ehted and immunoprecipitated with preimmune 
mouse sera. (Lane 8) Camp EBA-175 salt ehted and immunoprecipitated 
with sera from mice immunized with E-PCR-synthesized F seg. (Lane 
9) Camp EBA-175 salt eluted and immunoprecipitated with preimmune 
mouse sera. (Lane I0) Camp EBA-175 salt eluted and immunoprecipitated 
with sera from mice immunized with E-PCR-synthesized C  seg. (Lane 
11) Camp EBA-175 salt eluted and immunoprecipitated with mouse sera 
from mice immunized with wheat germ extract alone. 
Figure  1.  (A) Rebinding and sequential dution studies of EBA-175 and 
its 65-kD processed fragment utilizing rhE. EBPs (175 and 65 kD) used 
in the following experiments were affinity purified in thE binding assays 
(in the presence [lanes 1-3] or absence [lanes 5,  7, 8] of 2 mM PMSF), 
eluted with 1 M NaCI and dialyzed  before being used in rebinding experi- 
ments. EBPs were then rebound to untreated or treated rhE (in the pres- 
ence of PMSF), duted with 1 M NaC1 or 2-3 sialyllactose, and analyzed 
by 7.5% SDS-PAGE and fluorography.  (Lane I) Rebinding by EBA-175. 
Salt eluate of rebound EBPs. (Lanes 2 and 3) Sequential ehtion of rebound 
EBPs, first with 50 ram 2-3 sialyllactose (lane 2), then with 1 M NaC1 
(lane 3). (Lane 5) Salt ehate of rebound EBPs. (Lane 4) Rebinding of mixed 
EBPs to untreated rhE. Salt-eluted EBPs, initially  prepared in the presence 
(as in lane 1) and absence of PMSF (as in lane 5), were mixed in equal 
proportions, rebound, and salt elated from untreated thE. (Lane 6) Re- 
binding of mixed EBPs (prepared  as in lane 4) to neuraminidase-treated 
rhE. (Lanes 7 and 8) Sequential  elution of rebound EBPs, first with 2-3 
sialyllactose, then with 1 M NaCI. (Lane 9) Immunopredpitation of mixed, 
rebound EBPs (prepared as in lane 4) with antisera generated to peptide 
N1 (residues 354 to 377 in Camp EBA-175). (Lane 10) Immunoprecipita- 
tion of mixed, rebound EBPs (prepared as in lane 4) with antisera gener- 
ated to peptide 4 (residues 1062 to 1103 in Camp EBA-175). (B) Rebinding 
and sequential elation studies of EBA-175 and its 65-kD processed frag- 
ment utilizing huE. EBPs used in the following experiments were affinity 
purified in hue binding assays.  EBPs were eluted from huE with 1 M NaC1, 
dialyzed, and then rebound to untreated or neuraminidase-treated hue (in 
the presence of PMSF),  eluted with 1 M NaC1 or 2-3 sialyllactose, and 
analyzed by 10% SDS-PAGE and fluorography.  (Lane 1) Salt eluate of re- 
bound EBPs (prepared in the presence of PMSF).  (Lane 2) Salt eluate of 
EBPs (prepared  in the absence of PMSF).  (Lane 3) Rebinding of mixed 
EBPs to neuraminidase-treated huE.  Salt-eluted EBPs, initially prepared 
in the presence (as in lane I) or absence (as in lane 2) of PMSF, were mixed 
in equal proportions, rebound, and salt eluted from neuraminidase-treated 
huE.  (Lane 4) Rebinding of mixed EBPs (prepared  as in lane 3) to un- 
were mixed and rebound to untreated  rhE (Fig.  1 A,  lane 
4) and neuraminidase-treated  thE (Fig.  1 A, lane 6). In the 
latter case, only the lower band of the 65-kD doublet bound 
to the neuraminidase-treated the (Fig. 1 A, lane 6). Rebound 
EBA-175  and the 65-kD doublet were eluted off untreated 
rhE and immunoprecipitated either  with monospecific an- 
tisera to peptide N1 (residues 354 to 377 of Camp EBA-175) 
or to peptide 4 (residues  1062  to 1103 of Camp EBA-175). 
Antibodies to peptide N1 precipitated  only the lower band 
of the 65-kD doublet (Fig.  1 A, lane 9). Antibodies to pep- 
tide 4 precipitated only full-length EBA-175 (Fig. 1 A, lane 10). 
Results of rebinding and sequential elution using huE were 
identical except that, in these experiments,  only a single 65- 
kD fragment was recovered upon elution with salt. Its binding 
characteristics were the same as those described for the lower 
band of the 65-kD doublet recovered from thE (Fig.  1 B). 
In contrast to full-length EBA-175, the 65-kD fragment eluted 
from hue bound to neuraminidase-treated hue (Fig, 1 B, lane 
3) and was not eluted off huE with siallylactose  (Fig.  1 B, 
lanes 5 and 6). Therefore, using both rhE and huE, full-length 
EBA-175  and the 65-kD  fragment appeared to be binding 
to different erythrocyte  determinants.  In addition, in these 
experiments,  a 140-kD  sialic acid-independent erythrocyte 
binding protein first described by Dolan et al. (17) is observed 
(Fig.  1 B, lanes 3 and 6). The binding characteristics of this 
treated huE. (Lanes 5 and 6) Sequential dution of rebound EBPs (prepared 
in the absence of PMSF), first with 2-3 sialyUactose, then with 1 M NaC1. 
(Lane 7) Immunoprecipitation  of mixed rebound EBPs (prepared as in lanes 
3 and 4) with antisera to peptide 4 (residues 1062 to 1103 in Camp EBA-175). 
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bind to neuraminidase-treated hue (Fig. 1 B, lane 3) and both 
are eluted from huE with 1 M  NaC1 but not with siallylac- 
rose (Fig.  1 B, lanes 5  and 6).  These observations provide 
additional  evidence that  erythrocyte binding by the 65-kD 
fragment  is sialic  acid independent. 
To epitope map the location of the 65-kD fragment within 
EBA-175, immunoprecipitations with monospecific antisera 
generated to synthetic peptides of Camp EBA-175 were per- 
formed (Fig.  2).  The  65-kD  fragment  was precipitated by 
antisera  to  peptides  N1  (residues  354-377),  P2  (residues 
939-969), P5 (residues 970-1014),  and P6 (residues 1015-1061), 
but not by antisera  to P4,  suggesting that  the 65-kD frag- 
ment lies in the amino and middle region of EBA and does 
not  contain  the  peptide  4  region  of  EBA-175  (residues 
1062-1103). 
E-PCR Synthesis and Functional Analysis of EBA-175 Con- 
structs.  To further explore the binding characteristics  of EBA 
and its cleavage products, we synthesized radiolabded poly- 
peptides of EBA-175 using E-PCR. Overlapping constructs 
of EBA-175 (Fig. 3, top) were synthesized by E-PCR, trans- 
lated in vitro, and assessed for binding to hue (Fig. 3, bottom). 
Fragments containing,  but not exceeding, residues 869-982 
bound to huE. Residues 869-982, a region called C seg, cor- 
respond to one of the two described alleles of EBA-175. A 
second allele of EBA (5, 6) found in the strain FCR3 (F seg), 
was also expressed by E-PCR and analyzed for huE binding 
(Fig.  4).  Like the 65-kD  fragment,  both F  seg and C  seg 
bound  to untreated  (Fig.  4,  lanes 4,  5,  and 8)  and  neura- 
minidase-treated huE (data shown for C seg, Fig. 4, lane 6). 
In addition,  2-3 sialyUactose would not elute them off huE. 
To determine if C seg and F seg might be contained within 
the 65-kD fragments of Camp and FCR3, respectively, mice 
were directly immunized with E-PCR-generated C  seg and 
F seg. Interestingly, antisera generated to F or C seg precipi- 
tated the 65-kD fragment of Camp (Fig. 2), indicating that 
C seg is within the 65-kD fragment of Camp and that cross- 
reactive epitopes exist between F and C  seg despite their se- 
quence divergence.  Overall F seg and C seg share only m15% 
nudeotide or amino acid homology (5). However, when their 
primary amino acid sequences are aligned (GCG Software; 
University of Wisconsin),  a series of residues are conserved 
between these domains (Fig.  5).  17 (71%) of 24 residues in 
one region of F seg and C  seg are either identical (33%) or 
conservative substitutions  (38%). 
To define the smallest region of C  seg capable of binding 
to huE, overlapping polypeptides of C  seg were synthesized 
by E-PCR (Fig.  6 B) and analyzed for huE binding (Fig.  6 
A). Interestingly,  C  seg fragments,  C-Hinp and C-22, con- 
taining  most of the region of homology between F and C 
allelic regions, bound to hue (Fig. 6 A, and lanes I  and 2), 
but fragment  C-23, devoid of this segment (Fig.  6 A, lane 
3),  did  not.  A  peptide  (CP-I:  KATVSESSSSNTGLSIDD- 
DRNGDTFVRTQDTANTED) corresponding to the smal- 
lest binding domain of C seg was chemically synthesized and 
used in competitive binding experiments with native EBA- 
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Hgure 3.  In vitro synthesis  of EBA-175. (Top)  Constructs of  Camp EBA- 
175 synthesized  by E-PCR. Numbers refer to amino acid residues. Bold 
lines indicate synthesized  fragments that bound to huE (constructs 364- 
982; 759-982; and 869-982). (Bottom)  E-PCR synthesized  proteins were 
incubated with huE, spun through silicon oil, eluted with 1 M NaC1, 
and analyzed by 7.5% SDS-PAGE  and fluorography. (A) In vitro trans- 
lated EBA construct 21-1158. (Lane 1) Construct 21-1158  immunoprecipi- 
rated with antipeptide  4 antisera (50,000 counts). (Lane  2) Salt eluate from 
untreated hue incubated with construct 21-1158 (100,000 counts). (Lane 
3) Salt eluate from untreated hue incubated with construct 21-1158 im- 
munoprecipitated  with antipeptide  4 antisera (100,000  counts). (B) In vitro 
translated EBA construct 759-982. (Lane I) Construct 759-982 (50,000 
counts). (Lane  2) Salt eluate  from untreated hue incubated  with construct 
759-982 (10,000  counts). (Lane  3) Salt eluate  from untreated hue incubated 
with construct 759-982  (100,000  counts). (C) In vitro translated EBA con- 
struct 364-982. (Lane  I) Construct 364-982 (50,000  counts). (Lane  2) Salt 
ehate  from untreated hue incubated with construct 364-982 (10,000 
counts). (Lane  3) Salt eluate  from untreated huE incubated  with construct 
364-982 (100,000 counts). 
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Figure  4.  Binding analysis of E-PCR-synthesized C seg (Camp EBA- 
175) and F seg (FCR3  EBA-175). E-PC1L-synthesized  proteins were in- 
cubated with huE, spun through silicon oil, eluted with I M NaC1, and 
analyzed by 10% SDS-PAGE  and fluorography. (Lane 1) Salt eluate from 
neuraminidase-treated huE incubated with native Camp EBA-175. (Lane 
2) Salt duate from untreated huE incubated with native Camp EBA-175. 
(Lane 3) E-PCR synthesized C seg (50,000 counts/lane).  (Lane 4) Salt 
eluate from untreated huE incubated with C seg (50,000 counts/lane). 
(Lane 5) Salt eluate from untreated huE incubated with C seg (75,000 
counts/hne). (Lane  6) Salt  ehate from neuraminidase-treated  hue incubated 
with C seg (50,000 counts/lane). (Lane 7) E-PCR.-synthesized  F seg (50,000 
counts/lane).  (Lane 8) Salt eluate from untreated huE incubated with F 
seg (50,000 counts/lane). 
Figure  6.  (A) Functional mapping of C seg by E-PCR.  Analysis of 
E-PCR-synthesized overlapping fragments of C seg (113 amino acids cor- 
responding to residues  869-982 in Camp EBA-175)  bound and eluted from 
huE and analyzed by 17.5% SDS-PAGE  and fluorography. (Lane I) Salt 
eluate from hue incubated  with construct C-Hinp (residues 869-953; 50,000 
counts/lane). (Lane  2) Salt eluate from hue incubated with construct C-22 
(residues 898-982; 50,000 counts/lane). (Lane 3) Salt eluate from huE in- 
cubated with construct C-23 (residues 939-982; 50,000 counts/lane). (/3) 
Constructs  of C  seg synthesized in vitro by E-PCR. 
N-acetylneuraminic add (o~2-3)-Gal-determinants on O-linked 
carbohydrates of glycophorin A on the RBC membrane (12). 
Several lines  of evidence  indicate  that  EBA-175  is involved 
in the erythrocyte invasion process and suggest  that it may 
175 (Fig.  7). Peptide CP-1 in millimolar concentrations and 
antisera generated to it, inhibited binding of the 65-kD frag- 
ment to huE.  In contrast, peptide 4 inhibited binding of full- 
length EBA-175 but had no effect on binding of the 65-kD 
fragment. Of note, this putative binding domain represented 
by CP-1,  incorporates  71%  of the region of homology be- 
tween  F  seg and  C  seg. 
Discussion 
Merozoite attachment and invasion of uninfected erythro- 
cytes is a muhistep process, involving a sequence of adhesive 
events mediated by specific receptor-ligand interactions  (13, 
18-25).  EBA-175 is a P. fakiparum  antigen released into cul- 
ture supernatants that binds with receptor-like specificity to 
FCR3  900  ESSTITSPTESGSSDTEETPSISE 
:I::  :I:I  I  II  ::  :  II  : 
Camp  898  DSGS-GSATVSESSSSNTGLSIDD 
Figure  5.  Alignment  of FCR3 and Camp EBA-175 amino acid sequences 
beginning at residue 900 in FCR3 and 898 in Camp. Gaps (-) have  been 
introduced to optimize alignments; (I) identical residues, and (:) conserved 
residues between Camp EBA-175 in the region of C seg (bottom)  and FCR3 
EBA-175 in the region of F seg (top). 
Figure  7.  Inhibition of EBA-175 and the 65-kD fragment binding to 
erythrocytes by peptide CP-1 and anti-CP-1 sera. Samples  were bound to 
huE, salt eluted, and analyzed by 7.5% SDS-PAGE  and fluorography. (/1) 
Erythrocyte binding by EBA-175 and its 65-kD fragment in the presence 
of 1- (lane I), 10- (lane 2), and lO0-mM (lane 3) peptide CP-1, or lO0-mM 
peptide 4 (lane 4). (B) Erythrocyte binding by EBA-175 and its 65-kD 
fragment in the presence of 1/5,000 (lane I), 1/1,000 (lane 2), 1/100 (lane 
3), or 1/10 (lane 4) dilutions of rabbit anti-CP-1 sera. 
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proposed that EBA-175 may be a member of a family of malaria 
erythrocyte binding proteins based on the presence of con- 
served cysteine-rich regions present in the Duffy binding pro- 
teins of P. vivax and P. knowlesi and the EBA-175 of P..~l- 
ciparum. It is further postulated that the erythrocyte binding 
domain(s) of these molecules may reside in these conserved 
cysteine-rich  regions (26).  However, the molecular basis of 
the binding of uninfected RBCs by EBA-175 is unknown. 
In this study, we provide evidence for a two-stage binding 
process by EBA-175. 
Upon binding to hue or the in vitro, EBA-175 is cleaved 
to a 65-kD fragment that remains bound to the erythrocyte. 
Although it  is  not  known if EBA-175  is  proteolytically 
processed once bound to hue in vivo, the observation that 
the 65-kD fragment remains bound to the erythrocyte after 
proteolysis clearly suggests that an erythrocyte binding do- 
main for an unknown erythrocyte ligand is contained within 
this region of EBA-175. To characterize this putative binding 
domain within the 65-kD fragment, we first generated this 
fragment by binding native full-length EBA-175 to the rhE 
or huE, similar to the original experiments describing EBA- 
175 performed by Camus and Hadley (3). However, unlike 
Camus and Hadley, we than eluted the bound 65-kD product 
from RBCs, dialyzed it, and then examined its binding char- 
acteristics using rebinding and sequential elution studies. Only 
in this way was it possible to examine the binding of the 
65-kD fragment independent from the binding requirements 
of the intact EBA-175 molecule. With this approach we found, 
like others (3,  11), that full-length EBA-175 will not bind 
to sialic acid-deficient erythrocytes and can be eluted from 
untreated erythrocytes with soluble sialyllactose (Fig.  1, A 
and B) indicating that its initial recognition and binding is 
dependent upon a sialic acid-containing ligand on the eryth- 
rocyte surface. However, in contrast to full-length EBA-175, 
we demonstrated that the 65-kD fragment was not signifi- 
cantly eluted from erythrocytes with sialyllactose and bound, 
albeit in reduced amounts, to neuraminidase-treated erythro- 
cytes, suggesting that it is binding in sialic acid-independent 
manner. Thus, full-length EBA-175 and its 65-kD fragment 
appear to recognize different erythrocyte determinants. 
Two approaches were undertaken to map the 65-kD frag- 
ment and the putative sialic acid-independent binding do- 
main within this fragment. The first was to immunoprecipi- 
tate native EBA-175 and the 65-kD fragment using a series 
of monospecific antibodies generated to peptides of EBA-175 
(Fig. 2). The 65-kD fragment was precipitated by antibodies 
against peptides between residues 354 and 1061 but not be- 
yond 1062, indicating that the 65-kD fragment was local- 
ized to the amino and middle portion of EBA and corresponds 
to a region of EBA-175 recently implicated in erythrocyte 
binding based on homology with other malaria EBPs (26). 
The second approach to map the sialic acid-independent 
binding domain was to synthesize fragments of EBA-175 using 
E-PCR and assess them for erythrocyte binding. The use of 
E-PCR offers several advantages over traditional methods for 
the identification of functional domains. The synthesis of over- 
lapping regions of large proteins, such as EBA-175 can be 
accomplished in a more expeditious manner than standard 
cloning and subcloning procedures. The synthesized product 
does not contain any bacterial or viral protein, is not a fusion 
protein, and generally can be used in functional assays without 
purification. In addition, as we have shown here, it is pos- 
sible to rapidly generate antisera  to discrete gene products 
by directly immunizing with E-PCR synthesized protein. 
Using E-PCR-synthesized polypeptides, a RBC-binding do- 
main of Camp EllA was mapped to a 113 amino acid region 
from residues 869 to 982 (Fig. 3). Interestingly, this domain 
mapped to the allelic region (C seg) of Camp EllA-175. Simi- 
larly, when the other described allelic region of EBA-175 (F 
seg), derived from FCR3, was synthesized, it also bound to 
hue (Fig. 4). Erythrocyte binding by both F seg and C seg, 
like the 65-kD fragment, are sialic acid independent (Fig. 4) 
in that they bind to neuraminidase-treated hue and are not 
eluted from hue with 2-3 sialyllactose. Antisera generated 
to F and C seg, obtained by directly immunizing mice with 
E-PCR-synthesized protein, will precipitate their respective 
65-kD fragments, indicating they are contained within the 
65-kD fragment of each strain. It is intriguing that antibodies 
against F seg will also precipitate the 65-kD fragment of Camp, 
indicating the presence of a conserved immunogenic epitope 
between F seg and the Camp 65-kD fragment. Whereas there 
is little overall amino acid or base pair homology between 
the allelic regions of EBA-175, a series of amino acids and 
their primary structure are relatively  conserved between F 
seg and C seg (Fig. 5). In addition, binding analysis of over- 
lapping fragments of C seg (Fig. 6) define a putative binding 
domain of *40 amino acids (residues 903 to 943) that en- 
compasses most of this region of homology between F seg 
and C seg. Finally, a synthesized peptide (peptide CP-1) cor- 
responding to this region selectively inhibits binding of the 
65-kD fragment to huE, as does antisera generated to it. In 
contrast, peptide 4 inhibits the binding of full-length EBA-175 
but not its 65-kD fragment. 
Taken together, these data suggest that there are two dis- 
tinct binding domains within EBA-175.  We propose that 
EBA-175 may bind to erythrocytes by a two-stage process 
that includes a sialic acid-independent second step. During 
invasion, the initial binding of EBA-175 is dependent on the 
presence of a sialic-acid-containing determinant. The data 
presented here supports the hypothesis that after this initial 
binding, a second binding step occurs as a result of either 
a  receptor/ligand-induced conformational change  or  the 
limited proteolysis  of bound EBA-175 exhibited in vitro in 
this study. This second binding step is independent of the 
presence of sialic acid and maps to allelic regions within the 
65-kD fragment. Conserved residues  (Fig.  5) within these 
allelic regions may constitute the contact residues with an 
invariant but unknown RBC binding site. 
It is unknown if EBA-175 cleavage is a feature of erythro- 
cyte invasion in vivo, or an artifact  of our in vitro prepara- 
tion of this protein. Nonetheless, it is meaningful observa- 
tion suggesting that a conformational change occurring upon 
the initial binding of EBA-175 might expose regions involved 
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EBA-175  more susceptible to deavage. 
The concept that merozoites might bind by a two-step/site 
model was first proposed by Pasvol et al.  (20)  and later by 
Breuer (27).  According to  their scheme, the binding of a 
merozoite component to oligosaccharides on glycophorin A, 
exposed another domain, proximal to, or buried within the 
lipid bilayer. The second binding event would trigger inter- 
nalization of the merozoite. Our hypothesis that the sialic 
acid-dependent binding of EBA-175 initiates a conformational 
change or limited proteolysis permitting the next sequential 
event in invasion, is also supported by observations with polio 
and influenza viruses.  The proteolysis of polio capsid pro- 
teins is a prerequisite step to render virus particles competent 
to attach to specific cellular receptors. Upon binding to its 
cellular receptor, the polio virion undergoes irreversible con- 
formational changes, exposing an amphipathic helix that may 
contribute to viral entry into the target cell (28).  Similarly, 
after binding to its cellular receptor, cleavage of the influenza 
hemagglutinin (HA) is necessary for subsequent steps of viral 
infectivity, including membrane fusion and viral entry. Strains 
of influenza in which the HA are more readily cleaved dis- 
play increased pathogenicity. Cleavage of the HA permits a 
subsequent conformational change to expose a hydrophobic 
fusion peptide contributing to membrane fusion (29).  It is 
therefore conceivable that  our  proposed  receptor ligand- 
mediated conformational change or  deavage of EBA-175 
exposes similar hydrophobic regions resulting in membrane 
junction between the merozoite and erythrocyte, a necessary 
prerequisite for invasion (22). 
In our model, peptide 4 may form part of the rim of the 
binding pocket and may contribute to the first sialic acid-de- 
pendent stage of binding. Antisera generated to this peptide 
has been shown to inhibit parasite invasion in vitro and to 
block the sialic acid-dependent binding of full-length EBA- 
175 (4). Similarly, antibodies generated to the putative eryth- 
rocyte binding domain identified in C  seg may inhibit the 
second sialic acid-independent binding step. It is interesting 
to speculate that such an immune response may, in combina- 
tion with antisera to peptide 4, inhibit parasite invasion more 
effidently than antipeptide 4 antisera alone by inhibiting suc- 
cessive invasion steps. Even if this proves to be true, however, 
several strains of P.fakiparum can invade erythrocytes through 
sialic acid independent pathways (18,  30, 31),  therefore, an 
effective vaccine would also require the identification and in- 
hibition of receptor-ligand interactions involved in these al- 
ternate invasion pathways. 
The potential importance of F seg and C  seg is further 
supported by the observations that these allelic regions ap- 
pear to be uniquely and absolutely conserved. An analysis 
of 12 different laboratory clones and over 50 geographically 
diverse wild isolates revealed no isolate of P. fakiparum  that 
did not contain either F  or C  seg (5,  6). 
In summary, based on studies of a native protein and on 
E-PCR synthesized polypeptides, we provide evidence to sup- 
port a two-stage binding process by EBA-175 that includes 
a sialic acid-independent step. This sialic acid-independent 
binding domain resides within the 65-kD processed fragment 
of EBA-175 and appears to involve a homologous part of the 
dimorphic allelic region of EBA-175. 
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